USFDA Approval granted for Ganirelix Acetate injection

Ganirelix Acetate injection is indicated for inhibiting premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.

130
USFDA Drug product Approval
USFDA Approval

Last Updated on December 24, 2023 by The Health Master

USFDA Approval

USFDA Approval: The pharmaceutical landscape is witnessing a groundbreaking development as Lupin Limited, a global pharma major based in Mumbai, India, proudly announces the United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Ganirelix Acetate injection.

This 250 mcg/0.5 mL single-dose prefilled syringe marks Lupin’s foray into peptide-based injectables, reaffirming its dedication to pioneering healthcare solutions.

Understanding Ganirelix Acetate Injection

Ganirelix Acetate injection plays a crucial role in inhibiting premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.

This medical breakthrough addresses a significant aspect of women’s health, underlining the importance of Lupin’s innovative strides in pharmaceuticals.

Use of Ganirelix Acetate injection

Ganirelix Acetate injection is indicated for inhibiting premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.

The Significance of USFDA Approval

Receiving USFDA approval is a monumental achievement for Lupin Limited.

It not only validates the safety and efficacy of Ganirelix Acetate but also opens doors to a broader market, allowing Lupin to offer a generic equivalent to the reference listed drug (RLD) of Organon USA LLC.

This strategic move positions Lupin as a key player in the pharmaceutical industry.

Medical Indication and Market Potential

Ganirelix Acetate injection’s indication for inhibiting premature LH surges addresses a critical aspect of reproductive health.

With an estimated annual sales figure of USD 84 million in the US, according to IQVIA MAT September 2023, the market potential for this groundbreaking pharmaceutical product is substantial.

Ganirelix as Lupin’s First Peptide-Based Injectable

The approval of Ganirelix Acetate holds special significance as it marks Lupin’s entry into the realm of peptide-based injectables.

This diversification underscores Lupin’s dynamic approach to pharmaceutical development, promising advanced solutions for various medical conditions.

Estimated Annual Sales and Lupin’s Diverse Portfolio

The projected annual sales of Ganirelix Acetate injection highlight its economic potential.

This achievement adds another feather to Lupin’s cap, complementing its extensive portfolio of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).

Lupin’s Global Presence

With a presence in key regions globally, Lupin has strategically positioned itself to cater to diverse markets.

This global reach allows the company to contribute significantly to improving healthcare accessibility and affordability worldwide.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news